Apogenix's APG350 Effectively Induces Apoptosis of Tumour Cells via TRAIL Pathway Independent of Fc-Gamma Cross-Linking
Apogenix, a clinical-stage biopharmaceutical company, has announced that the data published in the December issue of Molecular Cancer Therapeutics demonstrate effective antitumour activity of the company's drug candidate APG350, an activator for TRAIL receptors. The publication shows that APG350's novel molecular structure allows for potent induction of apoptosis of tumour cells independent of the innate immune system, thus overcoming the limitations of other TRAIL receptor agonists.
"Due to the potential role of the TRAIL pathway in the treatment of cancer, there have been several attempts to develop substances for therapeutic use that utilise this pathway," said Harald Fricke, MD, Chief Medical Officer and Chief Operating Officer of Apogenix. "However, to date, none of these approaches has been successful in clinical trials. APG350 was designed to optimise both the activation of TRAIL receptors on tumour cells, as well as the pharmacokinetic properties of the substance. Its unique molecular structure ensures effectiveness without the need for cross-linking via Fc-gamma receptors on immune cells. As such cross-linking cannot be effectively achieved in the human body, previous TRAIL receptor agonists have ultimately failed to show antitumour efficacy in clinical studies."
"In the different colon carcinoma animal models that we examined, treatment with APG350 resulted in efficient induction of tumour-specific apoptosis and consequently the complete remission of the tumours. Because activation of the TRAIL signaling pathway is possible in many tumour types, APG350 has the potential for wide use in oncology. We are convinced that this novel drug design concept will be successful in clinical applications," Harald Fricke concluded.
The publication titled "APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fc-gamma Receptors" will appear in the print edition of Molecular Cancer Therapeutics tomorrow. The data are the result of a close collaboration of Apogenix with Prof. Simone Fulda, MD, from the University Hospital Frankfurt, Germany, and Prof. Peter Hohenberger, MD, from the University Medical Centre Mannheim, Germany. The electronic version of the publication is already available to subscribers of Molecular Cancer Therapeutics through the website of the American Association for Cancer Research.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance